{
  "source_pdf": "data/clinical_files/Arunachalam et al. (2021).pdf",
  "blocks": [
    {
      "id": "145707a4",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        191.35018920898438,
        745.3003540039062,
        2228.479736328125,
        1412.22216796875
      ],
      "text": "ung children and adults aged 65 and older1,2,4. Extra-pulmonary\nmplications of inﬂuenza infection constitute a further under-\ncognised disease burden4,5. Overall, such a high disease burden\nrries substantial social and economic cost6,7. Prevention of\nasonal inﬂuenza epidemics, as well as preparedness for future\nndemics, is thus a global priority.\nInﬂuenza A subtypes H1N1 and H3N2, and inﬂuenza B lineages\nYamagata and B/Victoria circulate routinely in humans and are\ncluded in seasonal inﬂuenza vaccines8. Inﬂuenza A subtypes can\no give rise to highly pathogenic viruses through cross-over from\nimal reservoirs to humans9. In the past century, four novel\nﬂuenza A virus strains have emerged in this way, each leading to\nglobal pandemic (H1N1 in 1918; H2N2 in 1957; H3N2 in 1968;\nd H1N1 in 2009). Vaccines against such strains are prepared and\nockpiled as government initiatives for emergency use in\ntential future pandemics.\nH\nl ti i\n(HA) i th\ni\nti\ni\nth\ni d\nti\nf\nthe identiﬁcation of the inﬂuenza strains and their like stra\nmost likely to spread during the upcoming season, for inclusio\nthe vaccine. Identiﬁcation of the target inﬂuenza strains is ba\non surveillance data collected by World Health Organiza\n(WHO) collaborating centres at six locations in the UK,\n(including the Centers for Disease Control and Prevention [CD\nJapan, China and Australia as part of the WHO Global Inﬂue\nSurveillance and Response System (GISRS)15. The ﬁnal decision\nresulting vaccine targets is made by individual regulatory bod\nInﬂuenza vaccines can afford signiﬁcant protection aga\ninﬂuenza illness, even when there is an antigenic misma\nagainst the predominant circulating virus strains16,17. Such cr\nprotection can occur through the priming of the immune sys\nby vaccination or natural infection and is primarily due\nantibodies speciﬁc to conserved regions on the HA head\nstem18. Vaccines that can induce immunity speciﬁc to circula\nild t\nt\ni\nd\nt\nti\nt\nl t d t\ni\nld",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9140146374702454,
        "detection_dpi": 300
      }
    },
    {
      "id": "37dc1b7c",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        146.04148864746094,
        1659.6253662109375,
        1184.0411376953125,
        2116.5302734375
      ],
      "text": "antibodies with rare speciﬁcities observed with RIV4. Furthermo\negg proteins, viral RNA or process impurities, typically found in\nreactions to these components in susceptible individuals with\nrecombinant HA vaccine thus provide a number of beneﬁts in\nsuch as for COVID-19.\nnpj Vaccines  (2021) 6:144 ; https://doi.org/10.1038/s41541-021-0\nINTRODUCTION",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9932520985603333,
        "detection_dpi": 300
      }
    },
    {
      "id": "d8679c52",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        144.43545532226562,
        2121.436767578125,
        1188.1158447265625,
        2537.31103515625
      ],
      "text": "The inﬂuenza vaccine ﬁeld has been constantly evolving to imp\nimprove the breadth and longevity of the protective immune re\nvaccines in development. Among these, the recombinant inﬂue\nsystem to express recombinant haemagglutinin (rHA) in insect\nstudied extensively. We describe how the unique structural featu\nto conventional inﬂuenza vaccines made from propagated inﬂu\nrecombinant proteins, unique post-translational processing of t\nstructural features. The absence of protease-driven cleavage an\ncertain conserved epitopes on HA molecules, which are likely res",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9944434762001038,
        "detection_dpi": 300
      }
    },
    {
      "id": "8486b1e7",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1258.2464599609375,
        2258.6728515625,
        2297.391845703125,
        2698.206787109375
      ],
      "text": "e the speed, scalability, and ﬂexibility of manufacturing, and to\nnse across age groups, giving rise to an array of next generation\nvaccine tetravalent (RIV4), using a baculovirus expression vector\ns, is the only one to have reached the market and has been\nof rHA in RIV4 improve protective immune responses compared\na virus. In addition to the sequence integrity, characteristic of",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9893654584884644,
        "detection_dpi": 300
      }
    },
    {
      "id": "54562103",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        142.72312927246094,
        2539.70556640625,
        1196.7894287109375,
        2922.582763671875
      ],
      "text": "REVIEW ARTICLE\nOPEN\nUnique features of a recombin\nvaccine that inﬂuence vaccine\nArun B. Arunachalam\n1✉, Penny Post2 and Deborah Rudin3",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9945418238639832,
        "detection_dpi": 300
      }
    },
    {
      "id": "779a7f65",
      "page_index": 0,
      "role": "Title",
      "bbox": [
        96.69562530517578,
        411.8708801269531,
        2233.24853515625,
        599.3492431640625
      ],
      "text": ",\ng\nhost cell entry and mediates the fusion of the viral envelope to the\nlate endosomal membrane. Neutralising antibodies that block HA\neffectively prevent viral entry into target cells and have been\nshown to protect the host from infection10,11. Another viral surface\nt i\ni id\n(NA)\nl\ni li\nid\nd\nl\ng\np\nThe annual production of inﬂuenza vaccine through conv\ntional, mostly egg-based platforms, is arduous and a ra\nagainst-time21. The production process, from the selection\ninﬂuenza\nstrains\nto\nvaccine\nmanufacture\nand\nrelease\ndi t ib ti\nt k\ni ht t\ni\nth\nh\nA il\nli",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9797730445861816,
        "detection_dpi": 300
      }
    },
    {
      "id": "457a9ce5",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1256.3270263671875,
        2704.37548828125,
        2288.054443359375,
        2915.603759765625
      ],
      "text": "nt haemagglutinin inﬂuenza\nerformance",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.993694007396698,
        "detection_dpi": 300
      }
    },
    {
      "id": "33066094",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1253.96435546875,
        1820.8641357421875,
        2291.26220703125,
        2233.2314453125
      ],
      "text": "HA in insect cells instills favourable tertiary and quaternary\nddition of simple N-linked glycans help to preserve and expose\nnsible for the high levels of broadly cross-reactive and protective\nthe presence of uniform compact HA oligomers and absence of\nventional vaccines, are expected to eliminate potential adverse\nuse of RIV4. These distinct structural features and purity of the\ncine performance which can be extended to other viral targets,\n3-7",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.966951847076416,
        "detection_dpi": 300
      }
    },
    {
      "id": "b39851b5",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1263.269287109375,
        1613.736328125,
        2294.204833984375,
        1818.40185546875
      ],
      "text": "budding virus from the infected cells, thus serving as another\nimportant vaccine target Although the presence of NA is not",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9854179620742798,
        "detection_dpi": 300
      }
    },
    {
      "id": "4872a07b",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        153.0836181640625,
        2989.25439453125,
        2276.85986328125,
        3067.751953125
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9866746068000793,
        "detection_dpi": 300
      }
    },
    {
      "id": "12805ea8",
      "page_index": 0,
      "role": "Title",
      "bbox": [
        145.1722869873047,
        1613.095458984375,
        411.40594482421875,
        1658.0140380859375
      ],
      "text": "INTRODUCTION\nSeasonal inﬂuenz",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9985186457633972,
        "detection_dpi": 300
      }
    },
    {
      "id": "61d23602",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        138.57806396484375,
        631.8672485351562,
        1140.6351318359375,
        677.7827758789062
      ],
      "text": "p\np\ng\nthus a key vaccine target. Expressed as trimeric glycoproteins",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9717476963996887,
        "detection_dpi": 300
      }
    },
    {
      "id": "5fcca4cf",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        211.48521423339844,
        1417.60595703125,
        1289.8583984375,
        1458.431884765625
      ],
      "text": "9–2020 season. These numbers are signiﬁcantly higher in\n1 2 4\nth",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6957452297210693,
        "detection_dpi": 300
      }
    },
    {
      "id": "7fe17cc9",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        181.13601684570312,
        228.7205810546875,
        1218.761474609375,
        1480.1209716796875
      ],
      "text": "POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE\nVIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE\nMUTATIONS IN THE HA PRIMARY STRUCTURE\nA known risk of traditional split or subunit vaccines is the potential\nfor the candidate vaccine virus or working virus seeds to acquire\nadaptive mutations as they grow in embryonated chicken egg or\nmammalian host cells during vaccine manufacture. Such adaptive\nmutations in HA peptides may reduce the effectiveness of the\nresultant vaccine24–26. Raymond et al.24 showed that an egg-\nadapted A/California/07/2009 (H1N1) vaccine strain acquired a\nmutation resulting in the substitution of glutamine with arginine\nat position 226 which in turn induced antibodies speciﬁc to\nreceptor binding site that bound to vaccine-derived HA preferen-\ntially over the circulating wild-type virus24. During the 2012–2013\nnorthern hemisphere inﬂuenza vaccination campaign, HA from an\negg-adapted A/Victoria/361/2011 (H3N2) virus used for vaccine\nmanufacturing differed from the WHO-recommended prototype\nand several other wild-type inﬂuenza viruses in three positions,\nH156Q, G186V, and S219Y25. The low vaccine effectiveness (41%)\nobserved for H3N2 in the 2012–2013 season was attributed to\nthese\nthree\nmutations\nduring\nvaccine\nproduction25.\nOther\nantigenic mutations introduced by egg-adaptation of the vaccine\nstrain\nduring\nvaccine\nmanufacturing\nare\nthought\nto\nhave\ncontributed to low vaccine effectiveness estimates for H3N2 in\nother inﬂuenza seasons26,27.\nLower vaccine effectiveness estimates have been observed for\nH3N2 than for other strains since 2009, even during seasons when\nthe selected vaccine strain appeared to be well matched to\ncirculating strains27. Differences in HA glycosylation between the",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9725326895713806,
        "detection_dpi": 300
      }
    },
    {
      "id": "e97b847c",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1290.3504638671875,
        1728.74853515625,
        2330.499267578125,
        2855.244140625
      ],
      "text": ",\np\na clade 3 C.2a H3N2 strain (A/Colorado/15/2014) containing\nthe new glycosylation site26. However, this particular glycosylation\nsite was absent in the egg-adapted virus. Consequently, anti-\nbodies induced in humans, and in ferrets, poorly neutralised the\nglycosylated clade 3 C.2a H3N2 strain26. Contrary to the egg-\nderived vaccines and as expected, rHA containing the new\nglycosylation site induced optimal levels of antibodies that\nefﬁciently recognised the glycosylated clade 3 C.2a H3N2 virus26.\nThe chances of introducing deleterious mutations through the\nadaptation of seed virus during vaccine manufacturing today are\nlow due to the stringent quality control of the working seed virus.\nIndeed, as per current regulatory requirements, seed viruses must\nbe conﬁrmed for both genetic and antigenic match with their\noriginating wild-type virus before they can be used for vaccine\nproduction. Nonetheless, the time it takes to generate appropriate\nseeds could hinder the timely availability of the vaccines.\nRecombinant DNA technology avoids the risk of the virus\nacquiring egg- or cell-adapted mutations during the manufactur-\ning process as it does not use ‘live’ inﬂuenza virus. Instead, DNA\ncoding for HA is cloned from a reference virus published in the\nGlobal Initiative on Sharing All Inﬂuenza Data (GISAID) database\nand is conﬁrmed for ﬁdelity at the working virus bank level28. As\nsuch, the primary amino-acid sequence of the rHA produced using\nbaculovirus or other recombinant expression system is identical to\nthe HA from the wild-type virus isolate selected for seasonal\ninﬂuenza vaccine production. Thus, the risk of antigenic mismatch\nof RIV4, or other rHA vaccines in development, with the wildtype",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9730799794197083,
        "detection_dpi": 300
      }
    },
    {
      "id": "428b2f83",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        194.16273498535156,
        1977.7298583984375,
        1218.97705078125,
        2894.999755859375
      ],
      "text": "p\n,\ngg\npp y\ny\np\nadoption\nof\nalternative\nvaccine\ndevelopment\napproaches\n(including mRNA, vector, and recombinant protein strategies)\nin\nthe\nurgent\nresponse\nto\nthe\nCOVID-19\npandemic\nhas\ndemonstrated the feasibility of using more efﬁcient methods to\nproduce new, effective vaccines within accelerated development\ntimelines. The recombinant quadrivalent inﬂuenza vaccine (RIV4,\nFlublok®, Supemtek® [EU, Canada], SanoﬁPasteur) was the ﬁrst\nlicensed inﬂuenza vaccine to be produced using recombinant\nviral proteins instead of antigens derived from live inﬂuenza virus\n(as for inactivated split-virion and subunit vaccines). RIV4 is an\nunadjuvanted vaccine containing 45 µg of HA/dose from each of\nthe four strains. The production of RIV4 is based on a novel\nproduction platform in which recombinant HA (rHA) is expressed\nin insect cells using a baculovirus expression vector system\n(BEVS)22. In brief, expresSF+ insect cells are infected with\nrecombinant baculovirus carrying the relevant inﬂuenza HA\ngenes, which are expressed under the control of a baculovirus\npolyhedrin promotor. rHA molecules from the infected cells are\nextracted using detergent and puriﬁed from the clariﬁed cell\nextract using column chromatographies followed by Q mem-\nbrane ﬁltration. Puriﬁed rHA is suspended in relevant buffer\nusing tangential ﬂow ﬁltration and passed through sterile",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9946531057357788,
        "detection_dpi": 300
      }
    },
    {
      "id": "f04e149a",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1291.782470703125,
        230.76925659179688,
        2331.773681640625,
        1100.8743896484375
      ],
      "text": "E. coli expression system has been shown to generate a high\nyields of rHA (200 mg/L of puriﬁed HA protein) using a minimal\nnumber of bioreactors31. The authors projected that the strategy\ncould yield up to half a billion doses of vaccine per month in a\nmedium-scale pharmaceutical production facility31. This approach\nwill likely shorten the entire vaccine manufacturing process32.\nHowever, E. coli-expressed rHA proteins can be subject to mis-\nfolding, contain impurities (e.g., host-cell proteins), and do not\nundergo glycosylation33. They therefore need extensive proces-\nsing to attain desired purity and to fold to their native\nconformation31.\nThe\nresulting\nprocessed\nproteins\nare\nless\nimmunogenic than egg-derived antigens, with around a 10-fold\ngreater quantity needed to generate protective immunity in\nanimal models31. These inherent complications have prevented\nlarge scale manufacturing and eventual commercialisation of\nE. coli-expressed inﬂuenza vaccines.\nVaccines containing plant-derived rHA either in soluble form or\nin virus-like particles (VLPs) have been shown to be safe and\nimmunogenic\nin\nhumans34–37.\nA\nplant-derived\nrecombinant\nquadrivalent VLP (QVLP) at 30 µg dose per strain was found to\nbe non-inferior in terms of vaccine efﬁcacy against respiratory",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.987955629825592,
        "detection_dpi": 300
      }
    },
    {
      "id": "7d4378db",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1288.319091796875,
        1112.9385986328125,
        2329.817138671875,
        1611.10791015625
      ],
      "text": "RECOMBINANT HA EXPRESSION SYSTEMS\nBoth prokaryotic and eukaryotic expression systems have been\nused for the manufacture of rHA vaccine antigens. The ﬁrst\ncandidate recombinant inﬂuenza vaccines to be successfully\nmanufactured using an Escherichia coli fermentation system\ninvolved expression of the globular head domain of the HA\nprotein genetically fused with the Toll-like receptor 5 agonist,\nSalmonella typhimurium ﬂagellin type 229. The resultant vaccines\nelicited strong and protective antibody responses in mouse\nmodels29. In Phase 1 clinical evaluation, a prototypic quadrivalent\nvaccine developed using this E. coli platform elicited immune\nresponses in healthy adults with favourable tolerability30. The",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9972021579742432,
        "detection_dpi": 300
      }
    },
    {
      "id": "a4f7fd3e",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        181.05581665039062,
        1489.771240234375,
        1230.2562255859375,
        1781.54833984375
      ],
      "text": "This review focuses on the structural features of BEVS derived\nrHA that make RIV4 unique from conventional vaccines, and how\nthese features help to maximise vaccine performance. Notably,\nthe beneﬁts of this manufacturing process can be extended to\nother viral targets, such as COVID-19, where the preservation of\nconserved epitopes is critical for imparting cross-protection\nagainst a constantly evolving and mutating virus.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.99432373046875,
        "detection_dpi": 300
      }
    },
    {
      "id": "91965374",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1298.6365966796875,
        2866.28173828125,
        2333.354736328125,
        3070.5341796875
      ],
      "text": "vaccine strains and circulating strains are thought to have\ncontributed to this reduced vaccine effectiveness26. During the\n2014–2015 inﬂuenza season, a clade 3 C.2a H3N2 strain possessing\na new predicted HA glycosylation site emerged26. For the\n2016–2017 season the inﬂuenza vaccine was updated to include",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9921697974205017,
        "detection_dpi": 300
      }
    },
    {
      "id": "e9b4efa4",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        191.1573486328125,
        2898.066162109375,
        1221.1905517578125,
        3066.502685546875
      ],
      "text": "and egg-free technologies allowing for guaranteed and faster\nmanufacture of inﬂuenza vaccines are needed to ensure timely\ndelivery for upcoming epidemic seasons and during potential\navian ﬂu pandemics, when egg supply may be impacted. The",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9849093556404114,
        "detection_dpi": 300
      }
    },
    {
      "id": "792532b9",
      "page_index": 1,
      "role": "Title",
      "bbox": [
        1290.057373046875,
        1681.9837646484375,
        2006.9637451171875,
        1727.8067626953125
      ],
      "text": "inﬂuenza strain selected for vaccines is elimin",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9973995685577393,
        "detection_dpi": 300
      }
    },
    {
      "id": "1545190a",
      "page_index": 1,
      "role": "Title",
      "bbox": [
        190.5597381591797,
        1850.9447021484375,
        1195.3612060546875,
        1970.1181640625
      ],
      "text": "ﬁltration for storage and formulation22. RIV4 has undergon\nextensive clinical assessment23, and was ﬁrst approved by FDA i\n2013. It is now licensed in the USA, Canada, Europe, Australi",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9583068490028381,
        "detection_dpi": 300
      }
    },
    {
      "id": "72d23235",
      "page_index": 2,
      "role": "Figure",
      "bbox": [
        384.3331604003906,
        234.7588348388672,
        2111.419921875,
        1025.177734375
      ],
      "text": "[FIGURE 1 - See figure_p3_72d23235.png]",
      "html": null,
      "image_path": "figures/figure_p3_72d23235.png",
      "metadata": {
        "score": 0.9970546960830688,
        "detection_dpi": 300
      }
    },
    {
      "id": "c9753804",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1259.042236328125,
        1241.0714111328125,
        2288.5048828125,
        1916.0948486328125
      ],
      "text": "g\ny\np\npurity of the vaccines considerably, as VLP structures also\nintegrated both baculovirus and Sf9 cell proteins. Elimination of\nthese unwanted proteins from the vaccine required extensive\ndisassembly and reassembly processing of puriﬁed VLPs, which is\na constraint for the commercial scale manufacturing of vaccines\nannually. It also raises the cost and the time it takes to bring the\nvaccines to the market. The yield and the cost of various\nmanufacturing processes and technologies are critical elements\nto ensure adequate supply of vaccine at an affordable cost,\nespecially in a pandemic situation. This aspect of the vaccine\nmanufacturing has been discussed exhaustively in a report\npublished by the Program for Appropriate Technology in Health\n(PATH) and is not covered here47.\nInsect cell-derived rHA (RIV4) has been studied extensively by\nvarious groups in both pre-clinical models and humans. The rHA\ncontained in RIV4 differs from that expressed in other systems in",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.994175910949707,
        "detection_dpi": 300
      }
    },
    {
      "id": "209c1c04",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        154.7352294921875,
        1248.270263671875,
        1185.8138427734375,
        2002.69677734375
      ],
      "text": "q\ninﬂuenza vaccine (QIV; Fluarix Quadrivalent, GlaxoSmithKline)\ngiven at 15 µg dose/strain in adults aged 18 to 64 years37.\nHowever, inconsistency in the expression levels of target proteins,\ndue to nonspeciﬁc integration of transgene(s) into the host\ngenome, has been a major challenge with plant-based expression\nsystems34. The unpredictable yield could adversely impact timely\nvaccine production, which typically involves updating at least one\nHA component of the vaccine to reﬂect antigenic change in\nthe circulating inﬂuenza viruses each season. A unique positive\nattribute of plant-derived rHA is that it can stimulate innate\nimmunity that predominantly facilitates Type 1 pro-inﬂammatory\ncellular immune responses, potentially as a direct effect of the\nplant-origin lipids/glycolipids in the vaccine formulation38. These\nstimulatory components in a plant-derived vaccine may need to\nbe controlled and kept at a constant level, for commercialisation,\nto avoid potential severe adverse events caused by enhanced\nimmune responses in vaccinees.\nSeveral groups have explored the use of adenovirus (AdV),",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9827455878257751,
        "detection_dpi": 300
      }
    },
    {
      "id": "1ab8e6e6",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1257.36572265625,
        1932.6710205078125,
        2288.104736328125,
        2515.87841796875
      ],
      "text": "by integrating HA, capsid protein (M1) and neuraminidase (NA)\nexpressed in insect cells44–46. Although presenting proteins in VLP\nstructures enhanced their immunogenicity it compromised the\nCapture\nPurify\nDNA removal\nTFF/Formulation\nPurification\nsystem for the manufacture of RIV4. BV baculovirus. Figure adapted\ne produced in insect cells. J Invertebr Pathol 107 Suppl, S31-41 © 2011",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9934252500534058,
        "detection_dpi": 300
      }
    },
    {
      "id": "30ca46c9",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        149.69422912597656,
        2559.199951171875,
        1181.455810546875,
        3070.940673828125
      ],
      "text": "Full-length cDNA\nPolyhedrin promoter\nTransfer plasmid\nProcessing Signals\nPCR-direct cloning\nFull-length cDNA\nLinearized BV DNA\nX\nX\nRecombination\n1. Cell seeding\n2\nExp\nin bio",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.997163712978363,
        "detection_dpi": 300
      }
    },
    {
      "id": "22fbcb9a",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        144.92835998535156,
        2020.760498046875,
        1176.074462890625,
        2547.137939453125
      ],
      "text": "illness and inﬂuenza like illness to a quadrivalent inactivated\nBV expression vector\nHA gene\nTFF=Tangential Flow Filtration\nFig. 1\nGeneration of rHA using the baculovirus-insect cell express\nfrom Cox, M. M. & Hashimoto, Y (2011). A fast track inﬂuenza virus va\nElsevier Inc, with permission from Elsevier23.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9952561259269714,
        "detection_dpi": 300
      }
    },
    {
      "id": "f40607fe",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1253.5703125,
        2681.99853515625,
        2292.539306640625,
        3066.76220703125
      ],
      "text": "ct with \ns bank\nn \nor\nDisc-stack\ncentrifugation\nHarvest\nExtraction\nDepth\nFiltration\nClarification",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9959486722946167,
        "detection_dpi": 300
      }
    },
    {
      "id": "d7734313",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        1240.04296875,
        2593.23681640625,
        2300.4228515625,
        2678.6787109375
      ],
      "text": "ctor",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9598753452301025,
        "detection_dpi": 300
      }
    },
    {
      "id": "90752dab",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        144.03558349609375,
        1097.662353515625,
        2289.452392578125,
        1214.1031494140625
      ],
      "text": "primarily as a replication defective vector, for gene delivery and\ntransgene expression of rHA in the host cells. AdV vectors induce\nboth cell-mediated and humoral immunity against the expressed\nprotein\nproviding\nrobust\nprotection\nagainst\nthe\ntargeted\nterms of speciﬁc structural features, the nature of the source\nmaterial and the manufacturing process, which have an impact on\ncertain aspects of vaccine safety and efﬁcacy (Fig. 2). Based on\nthese unique features RIV4 received ‘product exclusivity’ protec",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8445043563842773,
        "detection_dpi": 300
      }
    },
    {
      "id": "1896b5df",
      "page_index": 3,
      "role": "Figure",
      "bbox": [
        282.95819091796875,
        219.54559326171875,
        2119.048095703125,
        1491.1949462890625
      ],
      "text": "[FIGURE 1 - See figure_p4_1896b5df.png]",
      "html": null,
      "image_path": "figures/figure_p4_1896b5df.png",
      "metadata": {
        "score": 0.9956539869308472,
        "detection_dpi": 300
      }
    },
    {
      "id": "c177a85c",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1297.33056640625,
        1840.8834228515625,
        2316.119873046875,
        3073.787353515625
      ],
      "text": "ed\ncans\nExternal\nInternal\nMembrane\nN\n-S-S-\nUncleaved fusion\npeptide\nPaucimannose\nglycans\nDisulfide bond\nHA0\nHA0\nb",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9866936802864075,
        "detection_dpi": 300
      }
    },
    {
      "id": "15bac375",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        196.0677032470703,
        1831.6348876953125,
        1224.205322265625,
        2683.015869140625
      ],
      "text": "Fibrous\nStem\nPolysi\ncompl\nInter-disulfide bond\nHA1\nHA2\nExternal\nInternal\nMembrane\nN\n-S-S-\nN\nC\nCleaved fusion\npeptide",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9920712113380432,
        "detection_dpi": 300
      }
    },
    {
      "id": "fa4fa121",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        184.79371643066406,
        1542.2603759765625,
        2317.7314453125,
        1827.99658203125
      ],
      "text": "Internal\nC\nC\nFig. 2\nStructural features of native HA expressed on inﬂuenza virus and rHA produced in insect cells using the baculovirus expression\nvector system. a HA protein (shown as monomer) extracted from inﬂuenza virus is a heterodimer comprising HA1 (turquoise) and HA2\n(orange) linked though an inter-disulﬁde (S–S) bond and contains complex-type sialylated N-linked glycans. Cleaved fusion peptides (green\nand complex glycans74 eliminate and mask unique epitopes on HA respectively. b Recombinant HA protein (shown as monomer) expressed in\ninsect cells as a single precursor polypeptide (HA0) with amino acid sequence identical to wildtype HA sequence and contains unsialylated\npaucimannosidic N linked glycans74 HA0 is coloured in turquoise and orange to show HA1 and HA2 segments combined as a single",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9901682138442993,
        "detection_dpi": 300
      }
    },
    {
      "id": "bb72057d",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        189.3709259033203,
        2684.3388671875,
        1233.956787109375,
        3066.858642578125
      ],
      "text": "Globular\nHead\na",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.997729480266571,
        "detection_dpi": 300
      }
    },
    {
      "id": "9484e817",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        150.3646697998047,
        408.9344787597656,
        1193.4273681640625,
        1245.1343994140625
      ],
      "text": "g\np\nq\ng p y\nfor the release and the stability of RIV4.\nFurther\ncharacterisation\nby\ncryo-electron\nmicroscopy\nhas\nrevealed that the HA rosette clusters in RIV4 are uniformly\nstarﬁsh-shaped; whereas in the split vaccine they are mostly non-\nsymmetrical and agglomerated into huge structures, resulting in\nboth starﬁsh- and peanut-shaped heterogeneous particles55.\nAdditional electron microscopy analysis of split vaccine clusters\nshowed a highly heterogeneous mixture containing different\ntypes of viral particles containing HA and NA as well as split viral\nmembrane folded in various shapes, slightly disrupted virions, and\nwhole virions66.\nIn Canada between 2000 and 2004, an unusual number of\ncases of a syndrome termed as oculo-respiratory syndrome (ORS)\nwere reported following immunisation with the inactivated\ninﬂuenza split-virus vaccine68. Detailed analysis revealed that\nORS, induced within 2 to 24 h of vaccination, was suspected to\nbe due to the presence of micro-aggregates of unsplit virions in\nthe conventional egg-derived inﬂuenza vaccines69. High levels of\naggregate content in the split vaccine are believed to have",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9857302904129028,
        "detection_dpi": 300
      }
    },
    {
      "id": "365fa799",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1255.192626953125,
        2295.60791015625,
        2292.052001953125,
        3065.189697265625
      ],
      "text": "THE N-LINKED GLYCAN STRUCTURE OF RECOMBINANT HA\nPRODUCED IN INSECT CELLS DIFFERS SIGNIFICANTLY FROM\nHA IN OTHER INFLUENZA VACCINES\nInﬂuenza HA has a variable number of N-linked glycosylation sites\n(depending on the virus strain and subtype) in the globular head\nregion and the conserved stem region71. The glycosylation of HA\nhas various functions, including regulation of the virus life-cycle\nand a role in disease pathogenesis71. During vaccine manufacture,\nthe host cells used for the production of HA play a major role in\ndetermining\nHA\nN-glycan\ncomposition72,73.\nGlycoproteins\nexpressed in mammalian cells typically have sialylated complex-\ntype N-linked glycans, while those expressed in insect cells\ntypically have simple unsialylated glycans (either truncated,\npaucimannosidic\nor oligomannosidic\nglycans)74. An et al.72\nshowed that egg-derived and mammalian (Madin-Darby canine\nkidney) cell-derived HA predominantly contained highly-branched\ncomplex or high-mannose glycans, whereas HA expressed in Sf9\ninsect cells had relatively small paucimannose glycans (Fig. 2)72.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9925951361656189,
        "detection_dpi": 300
      }
    },
    {
      "id": "a1540b15",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1250.506103515625,
        1002.8510131835938,
        2285.50244140625,
        1664.72802734375
      ],
      "text": "g\ny\nwith broader protection12,71,76–80.\nIn a study by Nachbagauer et al.78, RIV4 induced HA stem-\nspeciﬁc neutralising antibodies directed against inﬂuenza subtypes\nH1, H3 and B haemagglutinin in an age-dependent manner in\nhumans, with the highest titres observed in the elderly78. RIV4 also\ninduces antibodies, in both humans and mice, that are speciﬁc to\nepitopes in the HA head region, at greater proportions than a\ntraditional mammalian cell-derived subunit vaccine (Flucelvax®\n[Trivalent])77. Higher magnitudes of haemagglutination inhibitory\nantibody response against HA1 have also been observed with RIV4\ncompared to egg- or mammalian cell-derived split vaccines\n(Flucelvax® Tetra, Seqirus, and Fluzone® quadrivalent SD, Sanoﬁ\nPasteur)60. These data warrant additional studies to verify whether\nrHA elicits a broader antibody repertoire than conventiona\nvaccines and whether this underlies the cross-protection against\nantigenic drift variants previously observed in clinical trials12,81.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9953752160072327,
        "detection_dpi": 300
      }
    },
    {
      "id": "d736c958",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1252.4686279296875,
        1676.37109375,
        2281.38134765625,
        2287.6591796875
      ],
      "text": "The peptide sequences around glycosylation sites are highly\nconserved and, as such, antibodies directed against these regions\ncould provide broader speciﬁcity. Antisera raised against simple\nmonoglycosylated HA in mice were shown to improve the breadth\nand capacity of HA-neutralising antibodies to protect against\nlethal challenge with H5N1 compared to antisera raised against\nfully glycosylated HA75. Thus, elimination of parts of glycans that\nare not essential for HA structure may improve vaccine-induced\nprotection. Subsequent studies showed that HA with simple\nglycans induce more broadly protective antibodies with superio\ncross-clade protection compared to HA with more complex\nglycans76–79. The presence of simpler glycans appears to be\nequally efﬁcient to that of chicken or mammalian cell-derived\nglycosylation in ensuring the proper folding of HA, and exposes\nconserved regions of the molecule for the induction of immunity",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9970657229423523,
        "detection_dpi": 300
      }
    },
    {
      "id": "4eb7d58f",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1260.9544677734375,
        362.94287109375,
        2290.14501953125,
        994.8902587890625
      ],
      "text": "g\np\ny\nRIV4 has a unique ability to induce broadly cross-reactive\nantibody responses to antigenically drifted A/H3N2 viruses in\nhumans. In a small study by Belongia et al.82, participants aged\n65–74 years were immunised with RIV4, a high-dose split-virion\ninactivated trivalent inﬂuenza vaccine (Fluzone® High Dose,\nSanoﬁPasteur; HD-IIV3) or adjuvanted-IIV3 (aIIV3)82. Participant\nsera were tested against four A/H3N2 viruses including a cell-\npropagated reference vaccine strain, two circulating viruses and\nan antigenically advanced virus with evidence of antigenic drift.\nThe post-vaccination geometric mean fold rise against the two\ncirculating viruses was twice as high for RIV4 as for HD-IIV3 or\naIIV3. Post-vaccination titre against the antigenically drifted\nH3N2 were generally low and similar across all groups, however,\nreceipt of RIV4 was strongly associated with seroconversion to\nthis strain (p = 0.003). The investigators suggested that although",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9909868836402893,
        "detection_dpi": 300
      }
    },
    {
      "id": "f25e549c",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        151.5138702392578,
        2531.369873046875,
        1181.06884765625,
        3066.334228515625
      ],
      "text": "clearly demonstrate structural differences between HA pre-fusion\nand post-fusion states, and the presence of unique neutralising\nepitopes in the pre-fusion HA0 molecules, which are present in\nRIV4 (Fig. 2).\nStructural differences in the HA polypeptides and rosettes\nbetween recombinant and split vaccines have been shown to\nresult in differences, both qualitative and quantitative, in the\nimmune response to vaccines in humans and animals. Portnoff\net al.64 demonstrated that recombinant HA antigens (speciﬁcally\nfor the H3 strain) produced using BEVS (as used for RIV4), induced\nsigniﬁcantly higher levels of broadly cross-reactive antibodies\nagainst highly conserved regions of the HA head and stem",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9943627119064331,
        "detection_dpi": 300
      }
    },
    {
      "id": "860705b7",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        156.9853057861328,
        1524.2713623046875,
        1178.3875732421875,
        2091.46875
      ],
      "text": "vaccine efﬁcacy and long-term immunity65.\nTHE HOMOGENEITY OF RECOMBINANT HA ANTIGENS IN RIV4\nMAY IMPROVE THE SAFETY PROFILE OVER CONVENTIONAL\nINFLUENZA VACCINES\nAs described above, HA is expressed on the viral surface as a HA\ntrimer (rosette). When these are extracted from inﬂuenza viruses,\nthey form clusters of varying sizes. This has been observed in\nconventional inﬂuenza virus-derived vaccines, with estimates of 18\nto 1100 trimers per cluster55,66,67. Two distinct populations of\ncluster have been observed; the majority have an average diameter",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9883168339729309,
        "detection_dpi": 300
      }
    },
    {
      "id": "77425a4b",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        146.88475036621094,
        2101.2197265625,
        1180.0067138671875,
        2525.574462890625
      ],
      "text": "domains than egg-derived split vaccines64. Recently Richards\net al.65 examined CD4 T-cell and antibody responses in healthy\nadults who received egg-derived split vaccine, cell-derived split\nvaccine or RIV4 for three successive inﬂuenza seasons (2015–2016,\n2016–2017, and 2017–2018)65. RIV4 elicited the most robust\nresponses, with signiﬁcantly higher T-cell and antibody levels than\nthe other two vaccines. Authors postulated that simpler glycosyla-\ntion of rHA and absence of other inﬂuenza viral proteins in RIV4\ncontributed to the observed robust immune response for RIV4 and\nemphasised the relevance of these features in determining",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9946081638336182,
        "detection_dpi": 300
      }
    },
    {
      "id": "83b1ca22",
      "page_index": 4,
      "role": "Title",
      "bbox": [
        1248.807861328125,
        236.425537109375,
        2272.021240234375,
        351.3176574707031
      ],
      "text": "the circulating A/H3N2 viruses were antigenically similar to th\ncell-grown vaccine reference virus, egg propagation of th\nvaccine strains had led to loss of a glycosylation site and",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9651209115982056,
        "detection_dpi": 300
      }
    },
    {
      "id": "eaf53169",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        148.13587951660156,
        241.05087280273438,
        1181.1058349609375,
        405.72998046875
      ],
      "text": "induced a Type-2 polarised immune response resulting in ORS\nbased on study results from a mouse model70. Although\nextremely rare, this is unlikely to occur with RIV4 that contains\nHA rosettes of small and uniform size.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9591505527496338,
        "detection_dpi": 300
      }
    },
    {
      "id": "0f5d3eae",
      "page_index": 4,
      "role": "Title",
      "bbox": [
        146.2445068359375,
        1395.1783447265625,
        1174.6197509765625,
        1523.607421875
      ],
      "text": "cluster have been observed; the majority have an average diameter\nof 150 nm, while the remainder are larger (average diameter\n5500 nm)66. However, the rosette clusters in RIV4 are uniform in size\nand presentation containing around six to eight HA trimers per",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9333096742630005,
        "detection_dpi": 300
      }
    },
    {
      "id": "60ab037f",
      "page_index": 5,
      "role": "List",
      "bbox": [
        1294.7120361328125,
        1509.9830322265625,
        2332.22509765625,
        3034.14990234375
      ],
      "text": "inﬂuenza vaccines that rely on inﬂuenza virions propagated in egg\nor mammalian cells, split with detergents with or without further HA\nenrichment. The use of recombinant protein technology eliminates\nthe risk of antigenic mismatch due to potential changes in primary\nHA structure through egg- or cell-adaptation. We also describe\nfeatures of the rHA tertiary structure that are likely to be responsible\nfor the generation of broad cross-reactive and protective antibodies,\ntogether with the direct or indirect evidence supporting this. The\nhomogeneity of rHA rosettes and\nnegligible\nprocess-related\nimpurities are the hallmarks of RIV4. As rHA production bypasses\nthe need for a viral inactivation step and avoids the use of eggs,\nrelated process-impurities such as inactivating agents or residual\negg-protein,\nand\nthus\npotential\nadverse\nreactions\nto\nthese\nimpurities in vulnerable individuals are eliminated. This well-\nestablished and validated platform for vaccine manufacture could\nbe extended to address other emerging infectious diseases where\ncross-protection against constantly evolving variants is critical, such\nas pandemic inﬂuenza and/or COVID-19.\nDATA AVAILABILITY\nNo data were generated for the review article.\nReceived: 24 May 2021; Accepted: 3 November 2021;\nREFERENCES\n1. Iuliano, A. D. et al. Estimates of global seasonal inﬂuenza-associated respiratory\nmortality: a modelling study. Lancet 391, 1285–1300 (2018).\n2. World Health Organization. Fact-sheet. Inﬂuenza (Seasonal). Available at https://\nwww.who.int/en/news-room/fact-sheets/detail/inﬂuenza-(seasonal). Accessed 12\nMarch 2021. (2018).\n3. Lafond, K. E. et al. Global burden of inﬂuenza-associated lower respiratory tract\ninfections and hospitalizations among adults: a systematic review and meta-\nanalysis. PLoS Med. 18, e1003550 (2021).\n4. US Centers for Disease Control and Prevention (CDC). Weekly U.S. Inﬂuenza",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9893486499786377,
        "detection_dpi": 300
      }
    },
    {
      "id": "f3fe1da8",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        1294.483154296875,
        241.11448669433594,
        2333.8701171875,
        987.0736083984375
      ],
      "text": "with inﬂuenza A2 and B viruses. Epidemiol. Infect. 70, 767–777 (1972).\n11. Ohmit, S. E. et al. Inﬂuenza hemagglutination-inhibition antibody titer as a cor-\nrelate of vaccine-induced protection. J. Infect. Dis. 204, 1879–1885 (2011).\n12. Dunkle, L. M. et al. Efﬁcacy of recombinant inﬂuenza vaccine in adults 50 years of\nage or older. N. Engl. J. Med. 376, 2427–2436 (2017).\n13. Wohlbold, T. J. & Krammer, F. In the shadow of hemagglutinin: a growing interest\nin inﬂuenza viral neuraminidase and its role as a vaccine antigen. Viruses 6,\n2465–2494 (2014).\n14. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Inﬂuenza\nneuraminidase: a neglected protein and its potential for a better inﬂuenza vac-\ncine. Vaccines 8, 409 (2020).\n15. World Health Organization. Global Inﬂuenza Surveillance and Response System\n(GISRS). Available at https://www.who.int/inﬂuenza/gisrs_laboratory/en/. Acces-\nsed 17 February 2021. (2021).\n16. Camilloni, B., Neri, M., Lepri, E. & Iorio, A. M. Cross-reactive antibodies in middle-\naged and elderly volunteers after MF59-adjuvanted subunit trivalent inﬂuenza\nvaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 27,\n4099–4103 (2009).\n17. Tricco, A. C. et al. Comparing inﬂuenza vaccine efﬁcacy against mismatched and\nmatched strains: a systematic review and meta-analysis. BMC Med. 11, 153 (2013).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9817473292350769,
        "detection_dpi": 300
      }
    },
    {
      "id": "92fa39d5",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        190.28550720214844,
        322.50799560546875,
        1227.9310302734375,
        1151.2158203125
      ],
      "text": "350 ng/mL89. Moreover, another study of commercial inﬂuenza\nvaccine preparations detected other viral proteins such as\nnucleoprotein and matrix protein (conﬁrmed by a chromato-\ngraphic separation) that are not shown to be relevant for vaccine\neffectiveness, and viral RNA fragments (conﬁrmed by activity\nassay)90,91. Such egg-derived or other inﬂuenza virus-derived\nproteins (as described above) and inﬂuenza viral RNA fragments\nare not present in recombinant vaccines.\nAlthough uncommon, some individuals may be at increased\nrisk of hypersensitivity reactions to component proteins such as\novalbumin and those who are sensitised may be at higher risk of\nclinical manifestations of allergic disease upon exposure92. Egg\nprotein, viral RNA, and process impurities such as inactivating\nagents or hydrocortisone that are typically present in conven-\ntional vaccines are absent in RIV4 would eliminate potential\nadverse reactions, although rare, to these components in\nvulnerable individuals93.\nCONCLUSIONS",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9622381329536438,
        "detection_dpi": 300
      }
    },
    {
      "id": "3495f6e4",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        188.38214111328125,
        1941.2216796875,
        1220.6795654296875,
        2475.330810546875
      ],
      "text": "vaccine results in increased titre of broadly neutralising HA stem-\nreactive antibodies and that these immune responses increase\nwith age78. This increase with age is possibly due to repeated\nexposure to divergent inﬂuenza viruses similar to the multiple A/\nH3N2 virus strains evaluated by Belongia et al.82. Therefore,\nvaccine constructs that preserve the highly conserved HA stem\ncan protect against drifted viruses and thus may confer a greater\nbreadth of protection against inﬂuenza.\nRECOMBINANT HA ANTIGENS ARE NOT SUBJECTED TO\nCHEMICAL MODIFICATIONS\nIn all conventional inﬂuenza vaccines, whether derived from eggs",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9940739274024963,
        "detection_dpi": 300
      }
    },
    {
      "id": "38fa0929",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        192.53128051757812,
        2485.867431640625,
        1227.0675048828125,
        2854.595458984375
      ],
      "text": "p\np\ng\ng\nA/H3N2 strains, including in older adults who are at a higher\nrisk for inﬂuenza and associated medical complications83,84. This\nunique characteristic of the recombinant vaccine is likely related\nto glycosylation of rHA in the insect cell line, leaving it uncleaved.\nThe higher quantity and greater accessibility of the genetically\nconserved stem region of rHA produced in insect cells (resulting\nin smaller N-linked glycans) may contribute to cross-protection\nagainst mismatched inﬂuenza strains12,75. The study by Nachba-\ngaeur et al.78 supports the hypothesis that a recombinant",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9976136684417725,
        "detection_dpi": 300
      }
    },
    {
      "id": "f6cd1dd1",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        190.20022583007812,
        1318.3218994140625,
        1228.0833740234375,
        1730.8226318359375
      ],
      "text": "g\np\ng\np\nfolding, conformation, and stability88. Unlike conventional vac-\ncines, RIV4 does not go through an inactivation step, thus\npreserving the native HA conformation of the wild-type virus,\nrequired for optimal protective immune response.\nABSENCE OF EGG OR OTHER INFLUENZA VIRAL COMPONENTS\nIN RECOMBINANT HA VACCINE IS LIKELY TO FAVOUR ITS\nSAFETY PROFILE\nAs most split and subunit vaccines are prepared from inﬂuenza",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9621477127075195,
        "detection_dpi": 300
      }
    },
    {
      "id": "8a0417ef",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        191.97695922851562,
        1226.6859130859375,
        1134.3919677734375,
        1313.1807861328125
      ],
      "text": "viruses that are grown in embryonated chicken eggs, they co\negg proteins. Testing of 58 vaccine lots covering six diff",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9947441816329956,
        "detection_dpi": 300
      }
    },
    {
      "id": "90c1f169",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        1299.429443359375,
        1060.5103759765625,
        1635.4708251953125,
        1104.8966064453125
      ],
      "text": "9. Paules, C. & Subbarao, K",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9969794750213623,
        "detection_dpi": 300
      }
    },
    {
      "id": "ace73035",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        186.99530029296875,
        2927.800537109375,
        436.25030517578125,
        2973.419677734375
      ],
      "text": "In addition to",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9971436858177185,
        "detection_dpi": 300
      }
    },
    {
      "id": "7e406c66",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        1297.578369140625,
        1398.6500244140625,
        1507.715087890625,
        1440.6624755859375
      ],
      "text": "5. Sellers, S. A.,",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9792590141296387,
        "detection_dpi": 300
      }
    },
    {
      "id": "01d17d8e",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        181.97328186035156,
        2982.251953125,
        1228.4598388671875,
        3066.619384765625
      ],
      "text": "impaired antibody response to circulating viruses, consistent\nwith previous reports26.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9624797701835632,
        "detection_dpi": 300
      }
    },
    {
      "id": "37f78282",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        191.4889373779297,
        1806.218505859375,
        1222.275390625,
        1932.914794921875
      ],
      "text": "or mammalian cells, the antigens are exposed to inactivation\nagents such as formaldehyde or β-propiolactone (BPL). These\ninactivating agents cause numerous modiﬁcations to the antigenic",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9541223049163818,
        "detection_dpi": 300
      }
    },
    {
      "id": "25d0a495",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        1291.1593017578125,
        1113.3970947265625,
        1864.6412353515625,
        1151.719970703125
      ],
      "text": "Suppl B, 11 15 (1999).\n8 Krammer, F et al Inﬂuenza Nat Rev Dis",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9609886407852173,
        "detection_dpi": 300
      }
    },
    {
      "id": "8a710252",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        1301.2755126953125,
        1197.3331298828125,
        2155.000244140625,
        1285.1015625
      ],
      "text": "review of the social and economic burden of inﬂuenza in low-\nincome countries. Vaccine 33, 6537–6544 (2015).\n7 Szucs T The socio economic burden of inﬂuenza J Antimicrob C",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.924001157283783,
        "detection_dpi": 300
      }
    },
    {
      "id": "8ef41d7f",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        179.94891357421875,
        243.16781616210938,
        1205.7362060546875,
        304.9764709472656
      ],
      "text": "The evidence reviewed here demonstrates several advantages o\nthe BEVS used in the manufacture of RIV4 over conventiona",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7101035714149475,
        "detection_dpi": 300
      }
    },
    {
      "id": "a37ed73e",
      "page_index": 6,
      "role": "List",
      "bbox": [
        135.5308074951172,
        266.00341796875,
        1246.43408203125,
        3049.697509765625
      ],
      "text": "18. Raymond, D. D. et al. Conserved epitope on inﬂuenza-virus hemagglutinin head\ndeﬁned by a vaccine-induced antibody. Proc. Natl Acad. Sci. USA 115, 168–173\n(2018).\n19. Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal inﬂuenza\nvaccine: different approaches for one goal. Virol. J. 15, 17 (2018).\n20. Nachbagauer, R. et al. A chimeric hemagglutinin-based universal inﬂuenza virus\nvaccine approach induces broad and long-lasting immunity in a randomized,\nplacebo-controlled phase I trial. Nat. Med. 27, 106–114 (2021).\n21. Orenstein, W. A. & Schaffner, W. Lessons learned: role of inﬂuenza vaccine pro-\nduction, distribution, supply, and demand–what it means for the provider. Am. J.\nMed. 121, S22–S27 (2008).\n22. Felberbaum, R. S. The baculovirus expression vector system: a commercial\nmanufacturing platform for viral vaccines and gene therapy vectors. Biotechnol. J.\n10, 702–714 (2015).\n23. Cox, M. M. & Hashimoto, Y. A fast track inﬂuenza virus vaccine produced in insect\ncells. J. Invertebr. Pathol. 107, S31–S41 (2011).\n24. Raymond, D. D. et al. Inﬂuenza immunization elicits antibodies speciﬁc for an\negg-adapted vaccine strain. Nat. Med. 22, 1465–1469 (2016).\n25. Skowronski, D. M. et al. Low 2012-13 inﬂuenza vaccine effectiveness associated\nwith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in\ncirculating viruses. PLoS ONE 9, e92153 (2014).\n26. Zost, S. J. et al. Contemporary H3N2 inﬂuenza viruses have a glycosylation site\nthat alters binding of antibodies elicited by egg-adapted vaccine strains. Proc.\nNatl Acad. Sci. USA 114, 12578–12583 (2017).\n27. Flannery, B. et al. Interim estimates of 2016-17 seasonal inﬂuenza vaccine\neffectiveness - United States, February 2017. MMWR Morb. Mortal. Wkly Rep. 66,\n167–171 (2017).\n28. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all inﬂuenza data - from\nvision to reality. Euro surveillance: bulletin Europeen sur les maladies transmis-\nsibles = European communicable disease bulletin 22, https://doi.org/10.2807/\n1560-7917.Es.2017.22.13.30494 (2017).\n29. Song, L. et al. Efﬁcacious recombinant inﬂuenza vaccines produced by high yield\nbacterial expression: a solution to global pandemic and seasonal needs. PLoS\nONE 3, e2257 (2008).\n30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent\nseasonal ﬂu vaccine comprising recombinant hemagglutinin-ﬂagellin fusion\nproteins. Open Forum Infect. Dis. 3, ofw015 (2016).\n31. Aguilar-Yanez, J. M. et al. An inﬂuenza A/H1N1/2009 hemagglutinin vaccine\nproduced in Escherichia coli. PLoS ONE 5, e11694 (2010).\n32. Saczynska, V. Inﬂuenza virus hemagglutinin as a vaccine antigen produced in\nbacteria. Acta Biochim Pol. 61, 561–572 (2014).\n33. Davis, A. R. et al. Immune response to human inﬂuenza virus hemagglutinin\nexpressed in Escherichia coli. Gene 21, 273–284 (1983).\n34. Rosales-Mendoza, S. et al. What does plant-based vaccine technology offer to the\nﬁght against COVID-19? Vaccines 8, 183 (2020).\n35. Pillet, S. et al. A plant-derived quadrivalent virus like particle inﬂuenza vaccine\ninduces cross-reactive antibody and T cell response in healthy adults. Clin.\nImmunol. 168, 72–87 (2016).\n36. Pillet, S. et al. Immunogenicity and safety of a quadrivalent plant-derived virus\nlike particle inﬂuenza vaccine candidate-two randomized Phase II clinical trials in\n18 to 49 and >/=50 years old adults. PLoS ONE 14, e0216533 (2019).\n37. Ward, B. J. et al. Efﬁcacy, immunogenicity, and safety of a plant-derived, quad-\nrivalent, virus-like particle inﬂuenza vaccine in adults (18-64 years) and older\nadults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396,\n1491–1503 (2020).\n38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant-\nderived\nvirus-like\nparticles\nbearing\ninﬂuenza\nhemagglutinin.\nVaccine\n36,\n8028–8038 (2018).\n39. Pandey, A. et al. Impact of preexisting adenovirus vector immunity on immu-\nnogenicity and protection conferred with an adenovirus-based H5N1 inﬂuenza\nvaccine. PLoS ONE 7, e33428–e33428 (2012).\n40. Sayedahmed, E. E. et al. Adenoviral vector-based vaccine platforms for devel-\noping the next generation of inﬂuenza vaccines. Vaccines 8, 574 (2020).\n41. Xiang, K. et al. Progress on adenovirus-vectored universal inﬂuenza vaccines.\nHum. Vaccin Immunother. 11, 1209–1222 (2015).\n42. Chen, J. R. et al. Better inﬂuenza vaccines: an industry perspective. J. Biomed. Sci.\n27, 33 (2020).\n43. Report to the president on reengeneering the inﬂuenza vaccine production\nenterprise to meet the challenges of pandemic inﬂuenza. Available at https://\nobamawhitehouse.archives.gov/sites/default/ﬁles/microsites/ostp/PCAST-\nInﬂuenza-Vaccinology-Report.pdf. Accessed August 2021.\n44. López-Macías, C. et al. Safety and immunogenicity of a virus-like particle pan-\ndemic inﬂuenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-\ncontrolled trial of adults in Mexico. Vaccine 29, 7826–7834 (2011).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8969917893409729,
        "detection_dpi": 300
      }
    },
    {
      "id": "a54645d5",
      "page_index": 6,
      "role": "List",
      "bbox": [
        1850.099609375,
        269.0315246582031,
        2306.708984375,
        2978.0029296875
      ],
      "text": "ction platform of complex virus-like\n2013).\nbal access. Available at https://path.\nubl_rpt_10-07.pdf. Accessed August\nreport. Supemtek. Procedure No.\n/www.ema.europa.eu/en/documents/\nessment-report_en.pdf. Accessed 17\ns [Updated 15 April 2021]. Available\nada/services/drugs-health-products/\nster-innovative-drugs.html.\nAcces-\nglutinin cleavage into HA1, HA2: no\n5, 9713–9715 (1998).\nmagglutinin with multibasic cleavage\ndoprotease. EMBO J. 11, 2407–2414\nnin precursor cleavage site, a deter-\norigin of the labile conformation. Cell\nof H5 highly pathogenic avian inﬂu-\nvage site motif. Rev. Med Virol. 25,\nd membrane fusion: a biophysical\n(2018).\nCharacterization of inﬂuenza vaccine\nn microscopy and image analyses\nin. Immunol. 23, 483–495 (2016).\nculoviruses as expression vectors for\nechnol. 10, 428–433 (1999).\n. Changes in the antigenicity of the\ns at acidic pH. Virology 126, 587–599\nation of viral epitopes recognized by\n. Microbiol. Immunol. 386, 323–341\numan monoclonal antibody induces\nding head domains. PLoS Biol. 17,\ns antibody afﬁnity maturation across\nmans. Nat. Commun. 10, 3338 (2019).\na highly conserved inﬂuenza virus\nn analysis of an antibody recognizing\n(2016).\ng of a transient intermediate in the\na virions. Sci. Adv. 6, eaaz8822 (2020).\nn nanoparticle vaccine elicits broadly\nistinct domains of H3N2 HA. Vaccines\nvaccine outperforms split and sub-\neciﬁc CD4 T cells and CD4 T cell-\nNPJ Vaccines 5, 77 (2020).\nsting methodologies for characteriza-\ns Immunother. 11, 1673–1684 (2015).\nemagglutinin antigens on inﬂuenza\nmicroscopy. Vaccines https://doi.org/\nratory syndrome following inﬂuenza\neillance through four inﬂuenza sea-\n217–225 (2005).\nassociated adverse events: results of\nan. Commun. Dis. Rep. 28, 189–196\nes the Th1/Th2 immune response to\nodel. J. Med. Virol. 72, 138–142 (2004).\nand 2009 inﬂuenza viruses: role of\nn. Sci. Transl. Med. 2, 24ra21 (2010).\ninﬂuenza vaccine hemagglutinins:\ne processing. J Virol. https://doi.org/",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8848515152931213,
        "detection_dpi": 300
      }
    },
    {
      "id": "a1ce9804",
      "page_index": 7,
      "role": "List",
      "bbox": [
        180.41607666015625,
        214.94456481933594,
        1213.521484375,
        2309.385986328125
      ],
      "text": "p\np\n2176–2185 (2006).\n81. Treanor, J. J. et al. Protective efﬁcacy of a trivalent recombinant hemagglutinin\nprotein vaccine (FluBlok(R)) against inﬂuenza in healthy adults: a randomized\nplacebo-controlled trial. Vaccine 29, 7733–7739 (2011).\n82. Belongia, E. A. et al. Clinical trial to assess immunogenicity of high-dose, adju\nvanted, and recombinant inﬂuenza vaccines against cell-grown A(H3N2) viruses\nin adults 65 to 74 years, 2017-2018. Vaccine 38, 3121–3128 (2020).\n83. Shinde, V. et al. Induction of cross-reactive hemagglutination inhibiting antibody\nand\npolyfunctional\nCD4+\nT-cell\nresponses\nby\na\nrecombinant\nmatrix-M\nadjuvanted hemagglutinin nanoparticle inﬂuenza vaccine. Clin. Infect. Dis\nhttps://doi.org/10.1093/cid/ciaa1673 (2020).\n84. Centers for Disease Control Prevention. Estimates of deaths associated with\nseasonal inﬂuenza — United States, 1976-2007. MMWR Morb. Mortal. Wkly Rep\n59, 1057–1062 (2010).\n85. Goldstein, M. A. & Tauraso, N. M. Effect of formalin, beta-propiolactone, mer\nthiolate, and ultraviolet light upon inﬂuenza virus infectivity chicken cell agglu\ntination, hemagglutination, and antigenicity. Appl. Microbiol. 19, 290–294 (1970)\n86. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P. & Metz, B. Reactions of beta\npropiolactone with nucleobase analogues, nucleosides, and peptides: implica\ntions for the inactivation of viruses. J. Biol. Chem. 286, 36198–36214 (2011).\n87. She, Y. M. et al. Surface modiﬁcations of inﬂuenza proteins upon virus inactiva\ntion by β-propiolactone. Proteomics 13, 3537–3547 (2013).\n88. Herrera-Rodriguez, J. et al. Inactivated or damaged? Comparing the effect o\ninactivation methods on inﬂuenza virions to optimize. Vaccin. Prod. Vaccin. 37\n1630–1637 (2019).\n89. Li, J. T., Rank, M. A., Squillace, D. L. & Kita, H. Ovalbumin content of inﬂuenza\nvaccines. J. Allergy Clin. Immunol. 125, 1412–1413 (2010). author reply 1413-1414\n90. Garcia-Canas, V. et al. Selective and quantitative detection of inﬂuenza virus\nproteins in commercial vaccines using two-dimensional high-performance liquid\nchromatography and ﬂuorescence detection. Anal. Chem. 79, 3164–3172 (2007)\n91. Garcia-Canas, V., Lorbetskie, B. & Girard, M. Rapid and selective characterization o\ninﬂuenza virus constituents in monovalent and multivalent preparations using\nnon-porous reversed-phase high performance liquid chromatography columns. J\nChromatogr. A 1123, 225–232 (2006).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9571035504341125,
        "detection_dpi": 300
      }
    },
    {
      "id": "210e3f5c",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1303.2215576171875,
        1776.4185791015625,
        2331.742431640625,
        2150.673095703125
      ],
      "text": "All authors are employees of SanoﬁPasteur and may hold shares and/or stock\noptions in the company.\nADDITIONAL INFORMATION\nCorrespondence and requests for materials should be addressed to Arun B.\nArunachalam.\nReprints and permission information is available at http://www.nature.com/\nreprints",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9892626404762268,
        "detection_dpi": 300
      }
    },
    {
      "id": "96723904",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1301.72998046875,
        558.8148193359375,
        2327.716064453125,
        740.3195190429688
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9961826205253601,
        "detection_dpi": 300
      }
    },
    {
      "id": "d646583b",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1300.2391357421875,
        870.8616943359375,
        2326.014404296875,
        1018.4540405273438
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9944116473197937,
        "detection_dpi": 300
      }
    },
    {
      "id": "8375293c",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1297.5806884765625,
        1145.3447265625,
        2323.789306640625,
        1217.3251953125
      ],
      "text": "regulation or exceeds the permitted use, you will need to obtain permission directly\nfrom the copyright holder. To view a copy of this license, visit http://creativecommons\norg/licenses/by/4 0/",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9920755624771118,
        "detection_dpi": 300
      }
    },
    {
      "id": "52133c49",
      "page_index": 7,
      "role": "Title",
      "bbox": [
        1292.155029296875,
        814.2831420898438,
        1734.6575927734375,
        859.8208618164062
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9975118637084961,
        "detection_dpi": 300
      }
    },
    {
      "id": "71d148a0",
      "page_index": 7,
      "role": "Title",
      "bbox": [
        1296.494384765625,
        504.477783203125,
        1681.550537109375,
        548.6792602539062
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9940576553344727,
        "detection_dpi": 300
      }
    },
    {
      "id": "eb2c558b",
      "page_index": 7,
      "role": "Title",
      "bbox": [
        1292.9578857421875,
        1293.5853271484375,
        1775.517822265625,
        1338.659912109375
      ],
      "text": "material in this article are included in t\nindicated otherwise in a credit line to t",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9873480796813965,
        "detection_dpi": 300
      }
    },
    {
      "id": "c6909835",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1291.46875,
        1347.0662841796875,
        2350.51318359375,
        1421.376953125
      ],
      "text": "appropriate credit to the original author(s) and the source, provide a link to the Creative\nCommons license, and indicate if changes were made. The images or other third party",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9703747034072876,
        "detection_dpi": 300
      }
    },
    {
      "id": "237735bb",
      "page_index": 7,
      "role": "Title",
      "bbox": [
        1292.9556884765625,
        1089.5889892578125,
        1697.933349609375,
        1135.501708984375
      ],
      "text": "g\ny",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9767045974731445,
        "detection_dpi": 300
      }
    },
    {
      "id": "7b458034",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1300.4769287109375,
        1573.2613525390625,
        2338.648681640625,
        1641.2421875
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9449321627616882,
        "detection_dpi": 300
      }
    },
    {
      "id": "477f5822",
      "page_index": 7,
      "role": "List",
      "bbox": [
        1287.00927734375,
        246.93333435058594,
        2338.906494140625,
        435.4658508300781
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7546926736831665,
        "detection_dpi": 300
      }
    },
    {
      "id": "fe8bff4f",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1293.2843017578125,
        1460.1217041015625,
        2333.750244140625,
        1525.4901123046875
      ],
      "text": "Open Access This article is licensed under a Creative Commons\nAttribution 4.0 International License, which permits use, sharing,",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7498843669891357,
        "detection_dpi": 300
      }
    },
    {
      "id": "24163890",
      "page_index": 7,
      "role": "Title",
      "bbox": [
        1297.630859375,
        2236.636474609375,
        1559.260498046875,
        2275.16064453125
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5745943784713745,
        "detection_dpi": 300
      }
    }
  ],
  "metadata": {
    "detection_dpi": 300,
    "total_pages": 8,
    "merge_settings": {
      "merge_overlapping": true,
      "merge_threshold": 0.3,
      "confidence_weight": 0.7,
      "area_weight": 0.3
    },
    "extraction": {
      "text_blocks": 69,
      "figure_blocks": 2,
      "figures_dir": "/Users/saul/projects/solstice/solstice/data/cache/Arunachalam_et_al.__2021_/extracted/figures"
    }
  },
  "reading_order": [
    [
      "779a7f65",
      "61d23602",
      "145707a4",
      "5fcca4cf",
      "12805ea8",
      "37dc1b7c",
      "d8679c52",
      "54562103",
      "b39851b5",
      "33066094",
      "8486b1e7",
      "457a9ce5",
      "4872a07b"
    ],
    [
      "7fe17cc9",
      "a4f7fd3e",
      "1545190a",
      "428b2f83",
      "e9b4efa4",
      "f04e149a",
      "7d4378db",
      "792532b9",
      "e97b847c",
      "91965374"
    ],
    [
      "72d23235",
      "90752dab",
      "209c1c04",
      "22fbcb9a",
      "30ca46c9",
      "c9753804",
      "1ab8e6e6",
      "d7734313",
      "f40607fe"
    ],
    [
      "1896b5df",
      "fa4fa121",
      "15bac375",
      "bb72057d",
      "c177a85c"
    ],
    [
      "eaf53169",
      "9484e817",
      "0f5d3eae",
      "860705b7",
      "77425a4b",
      "f25e549c",
      "83b1ca22",
      "4eb7d58f",
      "a1540b15",
      "d736c958",
      "365fa799"
    ],
    [
      "8ef41d7f",
      "92fa39d5",
      "8a0417ef",
      "f6cd1dd1",
      "37f78282",
      "3495f6e4",
      "38fa0929",
      "ace73035",
      "01d17d8e",
      "f3fe1da8",
      "90c1f169",
      "25d0a495",
      "8a710252",
      "7e406c66",
      "60ab037f"
    ],
    [
      "a37ed73e",
      "a54645d5"
    ],
    [
      "a1ce9804",
      "477f5822",
      "71d148a0",
      "96723904",
      "52133c49",
      "d646583b",
      "237735bb",
      "8375293c",
      "eb2c558b",
      "c6909835",
      "fe8bff4f",
      "7b458034",
      "210e3f5c",
      "24163890"
    ]
  ]
}